Therapeutic agent for fibrosis
Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.
1. A method for treating fibrosis scleroderma, comprising:
administering 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof to a patient.
2. The method of claim 1 , wherein the scleroderma is disseminated scleroderma.
3. The method of claim 1 , wherein the scleroderma is focal scleroderma.
4. The method of claim 1 , wherein the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is orally administered to the patient.
5. The method of claim 1 , wherein the salt is a methanesulfonate salt.
6. The method of claim 1 , wherein the salt is a monomethanesulfonate salt.
7. The method of claim 1 , wherein 0.005 to 5,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient.
8. The method of claim 1 , wherein 0.01 to 1,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient.